Ibandronic acid: new drug. Osteoporosis: one tablet a month, but risk of a 'flu-like' syndrome.
Monthly ibandronic acid therapy has not been compared with another bisphosphonate and there is no firm evidence that it reduces the risk of hip fracture. In contrast, it is associated with an increased risk of flu-like syndromes, arthralgia and myalgia. If daily use of bisphosphonate is inconvenient, it is better to switch to weekly alendronic acid therapy.
D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe; D005260:Female; D006801:Humans; D007251:Influenza, Human / Q000139:chemically induced; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
D004164:Diphosphonates